Incanthera Competitors and Similar CompaniesClear all
Incanthera's competitors and similar companies include G1 Therapeutics, Alpine Immune Sciences, Oncolytics Biotech and Alphamab Oncology.
 Incanthera Incanthera is a company that engages in the development of novel treatments for solid tumors (cancers). |  G1 Therapeutics G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. |  Alpine Immune Sciences Alpine Immune Sciences is a biotechnology company that develops protein-based immunotherapies. |  Oncolytics Biotech Oncolytics Biotech is a company developing Pelareorep, an intravenously delivered immuno-oncolytic virus, used for the treatment of solid tumors and hematological malignancies. | ||
Founding Date | Founding Date 2010 | Founding Date 2008 | Founding Date 2015 | Founding Date 1998 | Founding Date 2009 |
Type | Type Private | Type Public | Type Subsidiary | Type Public | Type Private |
Tags | |||||
Locations | Locations Manchester, GB HQ Bradford, GB | Locations Durham, US HQ | Locations Seattle, US HQ | Locations Calgary, CA HQ Calgary, CA San Diego, US | Locations Suzhou Shi, CN HQ |
Employees | Employees N/A | Employees 17015% increase | Employees 484% decrease | Employees 28 | Employees 42 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 377.2 m | Valuation ($) N/A | Valuation ($) 93.9 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $82.5m (FY, 2023) | Revenue (est.) $58.9m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $7.2m (FY, 2023) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $75.3m (FY, 2023) | Gross profit N/A | Gross profit N/A | Gross profit N/A |
Net income | Net income N/A | Net income ($48m) (FY, 2023) | Net income ($32.2m) (FY, 2023) | Net income ($28.8m) (FY, 2025) | Net income N/A |
Funding | |||||
Latest funding round | Latest funding round $ 1.1m (over 12 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 60m (about 7 years ago) |
Total funding raised | Total funding raised $ 1.1m | Total funding raised $ 289.6m | Total funding raised $ 49.3m | Total funding raised $ 24m | Total funding raised $ 160m |
For sources of this data, please see the company profile
View Company Profiles
G1 Therapeutics
HQ
Durham, US
Employees
170↑ 15% increase
G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer.
View companyAlpine Immune Sciences
HQ
Seattle, US
Alpine Immune Sciences is a biotechnology company that develops protein-based immunotherapies.
View companyOncolytics Biotech
HQ
Calgary, CA
Employees
28
Oncolytics Biotech is a company developing Pelareorep, an intravenously delivered immuno-oncolytic virus, used for the treatment of solid tumors and hematological malignancies.
View company
Alphamab Oncology
HQ
Suzhou Shi, CN
Employees
42
Alphamab Oncology is a clinical-stage biopharmaceutical company.
View company